Robert W. Baird upgrades Human Genome Sciences (Nasdaq: HGSI) from Neutral to Outperform and sets a $10 price target.

This article: 145 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE